Radar on Medicare Advantage
-
On SCOTUS Refusal to Review UHC Case, MAOs Must Tighten Chart Review and Coding Practices
Amid mounting attention to Medicare Advantage organizations’ risk adjustment and prior authorization practices — which were the subjects of intense discussion during a recent House Energy & Commerce Committee hearing — the U.S. Supreme Court last month declined to take up a case brought by UnitedHealthcare (UHC) challenging CMS’s 2014 Overpayment Rule. Industry experts tell AIS Health, a division of MMIT, that this decision means CMS can begin enforcing its rule and may soon finalize its long-awaited extrapolation methodology for conducting Risk Adjustment Data Validation (RADV) audits.
“I think given the makeup of the court, on the one hand it was a bit surprising that they declined to take the case and that the denial of cert was issued without a comment. But on the other hand, given the general political landscape and issues that the court is considering, this is fundamentally an issue of administrative law and they’ve considered some other administrative law cases this term and I can understand why they decided not to take this case,” remarks Lindsey Brown Fetzer, member with Bass Berry & Sims and chair of the firm’s managed care practice.
-
As PBMs Are Under Microscope, New Suit Accuses CVS of Generics-Blocking Scheme
At a time when the federal government is clamping down on pharmacy benefit managers and seeking ways to bring down prescription drug prices, a recently unsealed whistleblower complaint details how one of the three largest PBMs allegedly drove up costs for Medicare Part D beneficiaries and the federal government. In a lawsuit that CVS Health Corp. intends to fight, the False Claims Act complaint accuses the parent company of colluding with its “supposedly firewalled” entities — the SilverScript Part D subsidiary, PBM CVS Caremark and CVS pharmacies — of striking secret rebate agreements with the drug makers that required SilverScript to block substitution on its formularies of generic drugs in favor of costlier brand-name alternatives.
The U.S. Dept. of Justice chose not to intervene in the second amended complaint, which was filed in the U.S. District Court for the Eastern District of Pennsylvania in March and recently obtained by Stat. The suit was filed by relator Alexandra Miller, who worked for CVS Health for 19 years. According to Miller’s LinkedIn profile, she most recently served as senior director of Medicare Part D operations and is now senior director of member and provider experiences for Oscar Health.
-
IEHP, Mom’s Meals Hope to Replicate Successful CHF Pilot With Other Populations
Using a “tapered” meal delivery approach supported by plan-appointed navigators, Mom’s Meals and Inland Empire Health Plan (IEHP) last year cut both emergency room visits and hospitalizations in half for patients with congestive heart failure who participated in a six-month pilot. The program resulted in a significant medical cost savings and positive outcomes for patients, boding well for future applications in the IEHP population and in California’s recently launched CalAIM Community Supports program.
Patients with congestive heart failure (CHF) tend to have significantly high rates of recurring emergency department visits and hospitalizations, and upon discharge, many lack social supports to pursue the dietary and lifestyle changes that are needed to improve chronic care, according to Mom’s Meals, which provides fully prepared, refrigerated meals across the U.S. and serves the Medicaid, Medicare and individual markets. Since one of the key components of heart failure treatment is reducing sodium in the diet, Mom’s Meals provided lower-sodium (i.e., 600 mg less of sodium) fully prepared meals to members throughout the six-month pilot.
-
News Briefs: CMS’s Enhanced MTM Model Still Isn’t Showing Savings to the Medicare Parts A and B Programs
After four years, the Enhanced Medication Therapy Management (MTM) Model still has not generated any net savings to the Medicare program. Through the five-year model that started in January 2017, model participants tested a variety of interventions to improve Part D beneficiaries’ medication use. Despite efforts by some sponsors to alter their interventions, there continued to be no statistically significant impacts on Medicare Parts A and B expenditures for the overall enrollee population in model-participating plans, observed the Fourth Evaluation Report released by the CMS Innovation Center last month. Findings from subgroup analyses suggested that enrollees eligible for the low-income subsidy and enrollees with medically complex profiles did not benefit more from the model compared to the overall enrollee population, while the program saw decreases in inpatient expenditures and admissions related to the Ambulatory Care Sensitive Conditions for both the medically complex subgroup and the all-enrollee cohort, according to the report prepared by Acumen. -
Medicare Advantage Organizations Chase ‘Signature Trend’ of Offering Extra Benefits for 2023
Judicious enhancements to supplemental benefits was the common theme as Medicare Advantage organizations prepared their bids for 2023, according to actuaries who recently helped sponsors submit bids that were due on June 6. The benefit changes come as plans considered potential bonus payment losses in 2024 and other possible drivers of increased costs next year.
“The signature trend of this year was carrying forward a lot of the innovative benefits that we’ve seen take hold over the past few years,” remarks Tim Murray, principal with Wakely, an HMA company. These include “wallet” benefits such as over-the-counter card allowances and flexible “choose your own adventure” benefits often involving healthy food and/or groceries, he observes.

The Latest
Complimentary Publications
Premium Categories
Premium Categories
Meet Our Reporters
Meet Our Reporters